Research Reports in Clinical Cardiology
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Galectin-3: clinical utility and prognostic value in patients with heart failure
(3882) Total Article Views
Authors: Kramer F
Published Date February 2013
Volume 2013:4 Pages 13 - 22
|Received:||06 December 2012|
|Accepted:||03 January 2013|
|Published:||07 February 2013|
Clinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, Germany
Abstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.
Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- MLA'14 -
May 16–21, 2014
- Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
- The western diet and lifestyle and diseases of civilization
- Everolimus-eluting stents in interventional cardiology
- Transitioning from population to individualized preventive cardiology